PENDAHULUAN
1. WHO [internet]. Breast cancer. IARC; 2018 [cited 2018 November 29].
Available from:
http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf.
2. WHO [internet]. Globocan 2018 latest global cancer data. IARC; 2018
[Cited 2018 November 29]. Available from:
https://www.iarc.fr/infographics/globocan-2018-latest-global-cancer-data/.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torrre LA, Jemal A. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;
68:394- 424.
4. WHO [internet]. Breast cancer: prevention and control. World Health
Organization; 2018 [cited 2018 November 29]. Available from:
http://www.who.int/cancer/detection/breastcancer/en/.
5. Kementerian Kesehatan RI. InfoDatin. Jakarta: Pusat Data dan Informasi;
2016.
6. WHO [internet]. Indonesia .IARC; 2018 [cited 2018 November 29].
Available from: http://gco.iarc.fr/today/data/factsheets/populations/360-
indonesia-fact-sheets.pdf.
7. Banurekhaa B. Prevalensi kanker payudara pada wanita di RSUP H. Adam
Malik pada tahun 2009 [student paper]. Medan: Universitas Sumatera
Utara; 2011 [cited 2017 May 14]. Available from:
http://repository.usu.ac.id/handle/123456789/21569.
8. Taha MNA. Prevalensi dan karakteristik penderita kanker payudara di
Departemen Bedah RSUP H. Adam Malik Medan tahun 2010 [student
paper]. Medan: Universitas Sumatera Utara; 2012 [cited 2017 May 14].
Available from:
http://repository.usu.ac.id/handle/123456789/31030.
9. Fandini I. Karakteristik penderita kanker payudara di RSUP H. Adam
Malik Medan tahun 2016 [student paper]. Medan: Universitas Sumatera
Utara; 2017 [cited 2018 December 2]. Available from:
http://repositori.usu.ac.id/handle/123456789/4539.
10. Dogan S., Andre F., Arnedos M. Issues in clinical research for metastatic
breast cancer. Current Opinion in Oncology. 2013;25(6):625–629. doi:
10.1097/cco.0000000000000018. [PubMed] [CrossRef] [Google Scholar]
11. Georgalas I, Paraskevopoulos, Koutsandrea C, Kardara E, Melamos P,
Ladas D, et al. Ophtalmic metastasis of breast cancer and ocular side
effects from breast cancer treatment and management: Mini Review.
Biomed Res Int. 2015:1-8.
12. Gerber B, Freund M, Reimer T. Recurrent breast cancer treatment
strategies for maintaining and prolonging good quality of life. dtsch arztebl
int. 2010;107:85-91.
13. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in
cancer therapy. J Clin Oncol 2015;33:1974–82.
14. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PDL1
antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–
65.
15. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in
the escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA 2002;99:12293–7.
16. Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1
checkpoint blockade immunotherapy. Cancer Treat Rev 2015;41:868–76.
17. Schutz F, Stefanovic S, Mayer L, et al. PD-1/PD-L1 pathway in breast
cancer. Oncol Res Treat 2017;40:294–7.
18. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in
triple-negative breast cancer. Cancer Immunol Res 2014;2:361–70.
19. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and
its ligand (PD-L1) in common cancers and their correlation with molecular
cancer type. Cancer Epidemiol Biomarkers Prev 2014;23:2965–70.
20. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and
ipilimumab or monotherapy in untreated melanoma. N Engl J Med
2015;373:23–34.
21. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl J Med
2015;373:1803–13.
22. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in
advanced squamous-cell non-small-cell lung cancer. N Engl J Med
2015;373:123–35.
23. Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death
ligand 1 (PD-L1) is associated with poor prognosis in human breast
cancer. Breast Cancer Res Treat 2014;146:15–24.
24. Qin T, Zeng YD, Qin G, et al. High PD-L1 expression was associated with
poor prognosis in 870 Chinese patients with breast cancer. Oncotarget
2015;6:33972–81.
25. Zhang M, Sun H, et al. Expression of PD-L1 and prognosis in breast
cancer: a metaanalysis. Oncotarget, Advance Publications 2017:1-8.
26. ShiChao Li, Li Chen, et al. Role of programmed cell death ligand-1
expression on prognostic and overall survival of breast cancer. Medicine
2019:1-8.